abstract: Immunotherapy is moving forward in prostate cancer. The autologous vaccine, Sipuleucel-T has been the first vaccine to be approved by FDA. First results with GVAX, tasquinimob or anti-PD-1 have been disappointing. Ipilimumab seen to be more active at an earlier stage of prostate disease. Identifying predictive factor or surrogate markers of activity of immunotherapy and which agents are clinically effective alone or in combination with others therapies such as hormonal or bone targeted therapies are warranted.
authors.affiliation: Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, Sorbonne-Paris-Cité, France; INSERM U970 PARCC université Paris-Descarte, Paris France. Electronic address: stephane.oudard@aphp.fr.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
authors.affiliation: Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Constance
authors.initials: C
authors.lastname: Thibault
authors.affiliation: Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Angelergues
authors.affiliation: INSERM U970 PARCC université Paris-Descarte, Paris France.
authors.forename: Eric
authors.initials: E
authors.lastname: Tartour
authors.affiliation: Service d'urologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Marc Olivier
authors.initials: MO
authors.lastname: Timsit
authors.affiliation: Service d'urologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Mejean
authors.affiliation: Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Constance
authors.initials: C
authors.lastname: Michel
authors.affiliation: Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; CRC UMRS1138 EQ13, 15, rue de l'École-de-Médecine, 75006 Paris, France.
authors.forename: Yann
authors.initials: Y
authors.lastname: Vano
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D006801:Humans; D056747:Immunomodulation / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D000077269:Lenalidomide; D008297:Male; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011804:Quinolines / Q000627:therapeutic use; D015363:Quinolones; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; C000593794:GVAX vaccine; D000074324:Ipilimumab; C105992:PDCD1 protein, human; C588274:PROSTVAC; D061026:Programmed Cell Death 1 Receptor; D011804:Quinolines; D015363:Quinolones; D014020:Tissue Extracts; D014614:Vaccines, Synthetic; D000077594:Nivolumab; D013792:Thalidomide; C516109:tasquinimod; C511774:sipuleucel-T; D000077269:Lenalidomide
keywords: Checkpoint inhibiteurs; Checkpoint inhibitor; Urologie; Urology; Vaccines; Vaccins